nimotop nimodipine 50ml 10mg per vial 1vial per carton

Description

Indication & Scope

Nimotop® is a prescription calcium channel blocker indicated for the prevention and treatment of cerebral vasospasm-related ischemic neurological deficits following aneurysmal subarachnoid hemorrhage. It may also be used during the recovery phase of acute cerebrovascular disorders to improve cerebral circulation.

Mechanism: Nimodipine selectively blocks L-type calcium channels in cerebral vascular smooth muscle, reducing calcium influx, relaxing cerebral arteries, improving cerebral blood flow, and reducing ischemic brain injury caused by vasospasm.
Drug class: Dihydropyridine calcium channel blocker (CCB).
Clinical use: Prevention and treatment of delayed cerebral ischemia caused by cerebral vasospasm after aneurysmal subarachnoid hemorrhage under hospital monitoring.

Specification

Generic Name	Nimodipine Injection
Brand Name	Nimotop®
Ingredient	Nimodipine
Dosage Form	Injection
Package	50 ml: 10 mg/vial/carton
Conditions Treated	Cerebral vasospasm after aneurysmal subarachnoid hemorrhage
Taboos	Hypersensitivity to nimodipine or any component of the product; severe hypotension; pregnancy and breastfeeding.
Place of origin	Germany
Prescription type	Prescription Drug (Rx)
Storage Conditions	Store below 25°C, protect from light.
Manufacturer	Solupharm Pharmazeutische Erzeugnisse GmbH
Registration Authority	National Medical Products Administration (NMPA), China
Approval Number	HJ20181107
Approval Date	July 4, 2022
Shelf Life	24 months

How to use ?

Recommended Dose: Initial infusion: 1 mg/hour for the first 2 hours. If tolerated, increase to 2 mg/hour. Patients with body weight below 70 kg or unstable blood pressure should start at 0.5 mg/hour.

Time: Continuous intravenous infusion for 10–14 days after subarachnoid hemorrhage under specialist monitoring.

Instructions for use: Administer by intravenous infusion only. Use the supplied light-protected infusion system. Monitor blood pressure and heart rate during treatment.

Interaction: CYP3A4 inhibitors may increase nimodipine exposure, while CYP3A4 inducers may reduce its effect. Combination with other antihypertensive drugs may increase the risk of hypotension.

Side effects: Common adverse reactions include hypotension, headache, dizziness, flushing, nausea, and palpitations. Serious reactions include severe hypotension, bradycardia, allergic reactions, and infusion-related complications.

Important Notice

This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indication, and regional regulatory requirements.

Packaging & Shipping

Packaging

Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.

Shipping Methods

Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.

Export Support

Certificate of Analysis

GMP Certificate

Commercial Invoice

Packing List & CPP

Cold Chain Logistics

Customs Documentation

Scientific and regulatory sources

1.WHO References

2.NMPA

3.FDA

4.EMA

FAQ

What is Nimotop® used for?

Nimotop® is used to prevent and treat cerebral vasospasm and delayed cerebral ischemia following aneurysmal subarachnoid hemorrhage.

How is Nimotop® administered?

Nimotop® is administered by continuous intravenous infusion in a hospital under specialist supervision with blood pressure and heart rate monitoring.

How long is Nimotop® treatment usually given?

Intravenous treatment is typically continued for 10–14 days after subarachnoid hemorrhage, followed by oral nimodipine if clinically appropriate.

Why must Nimotop® be protected from light?

Nimodipine is light-sensitive. The infusion solution should be protected from light during administration to maintain drug stability and effectiveness.